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It is unclear whether hyperglycaemia or diabetes mellitus are risk factors for a first
venous thrombosis (VT). Self-reported diabetes status and fasting glucose (FG)
measures were collected from the Multiple Environmental and Genetic Assessment
(MEGA) study to confirm these associations. FG levels were categorized based on
the World Health Organization criteria [<61 (reference), 61–70 (2nd), ≥70 (3rd)
mmol/l]. Logistic regression was performed to quantify the associations. Neither
increased FG levels [Odds ratio (95% confidence interval): 098 (069–137) 2nd vs.
reference, 097 (058–163) 3rd vs. reference] nor self-reported diabetes [112 (080–
158)] were associated with an increased risk of a first VT.
Keywords: hyperglycaemia, venous thrombosis, type 2 diabetes mellitus,
case-control studies, odds ratio.
In recent years, several studies indicated that venous throm-
bosis (VT) and atherosclerotic cardiovascular disease (CVD)
might share common risk factors (Lijfering et al, 2011).
Diabetes mellitus, a chronic metabolic disease that is associ-
ated with CVD, is diagnosed by elevated fasting glucose
levels and has been increasingly investigated as a possible
risk factor for VT (Petrauskiene et al, 2005; Heit et al, 2009;
Stein et al, 2009). In several case-control studies, glucose
levels were measured at the time of the VT diagnosis; these
levels may have been affected by the thrombotic event (i.e.,
acute phase effect), rather than representing levels before the
event (Hermanides et al, 2009; Tichelaar et al, 2011; Cohn
et al, 2012).
In the current study, we explored whether fasting glucose
levels (after VT events were diagnosed, as a surrogate for
glucose levels before the event), are associated with an
increased risk of a first VT in a non-diabetic population
without a recent cancer diagnosis. Furthermore, we studied
the association between self-reported diabetes and the risk
of a first VT. Analyses were performed in a large, popula-
tion-based case-control study, the Multiple Environmental




The MEGA study is a population-based case-control study
investigating the aetiology of VT. The study design was
approved by the Ethics Committee of the Leiden University
Medical Centre, the Netherlands, and written informed con-
sent was obtained from all participants. From 1999 to 2004,
4956 consecutive VT patients with an objectively confirmed
first event of VT or pulmonary embolism (PE) were included
in the study. The control subjects were recruited from two
sources, i.e., partners of VT patients without a history of VT
(n = 3297); and from the general population, by random-
digit dialling (RDD), further matched for age and sex with
the VT cases (n = 3000). A detailed description of study
design, study population selection and VT risk factor assess-
ment can be found in the Appendix S1.
Laboratory tests
Patients and controls visited one of the anticoagulation clin-
ics for an interview and blood sampling at least 3 months
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after discontinuation of anticoagulation, or during anticoagu-
lant therapy in patients who continued this therapy for more
than 1 year. Glucose levels were measured on stored
(80°C) and previously unthawed fasting serum samples by
hexokinase method on a Modular P800 Clinical Chemistry
analyser (Roche Diagnostics, Mannheim, Germany).
Fasting glucose concentrations were firstly categorized into
three categories according to the World Health Organization/
International Diabetes Federation (WHO/IDF) criteria for
diagnosing diabetes mellitus and intermediate hyperglycaemia
(≤60, ≥61 and <70, ≥70 mmol/l, respectively) (WHO/IDF
2006). Additionally, they were categorized into quintiles
based on the empirical fasting glucose distribution from the
entire MEGA control population [<45 (<25th), 45–48
[25th–50th), 48–52 [50th–75th), 52–66 [75th–975th),
≥66 mmol/l (≥975th)].
Statistical analyses
Logistic regression models were used to estimate the odds
ratios (OR) with 95% confidence intervals (95% CIs) for the
associations of continuous and categorized fasting glucose
levels with a first event of VT. In the basic model, age- and
sex-adjusted ORs with 95% CIs were estimated. In addition,
oestrogen use at both index date and blood draw, body mass
index, statin use at blood draw and C reactive protein levels
were added as confounders in a fully adjusted model. To
adjust for lifestyle as a confounder in a model, we performed
an additional 1:1 matched analysis by conditional logistic
regression, taking only the VT patient partner controls into
account. The risk of VT associated with fasting glucose levels
was estimated for provoked and unprovoked VT events sepa-
rately. Unprovoked VT was defined previously (van Hyl-
ckama Vlieg et al, 2014). Several sensitivity analyses were
performed in addition to the main analyses to assess the
robustness of the risk estimates (Appendix S1). To determine
whether diabetes is a risk factor for VT, two models with dif-
ferent confounders (basic model and fully adjusted model)
were taken into account in both the logistic as well as condi-
tional logistic regression, similarly to the analyses described
above. In addition, analyses were performed both for pro-
voked and unprovoked VT.
All statistical analyses were performed with SPSS for Win-
dows, release 23 (SPSS Inc, Chicago, IL, USA).
Results
The baseline characteristics of all participants in both analy-
ses are summarised in Table SI. No association was found
between fasting glucose levels as a continuous variable and
the risk of VT (OR: 097, 95% CI 089–105) in the fully
adjusted model (Table I). After categorizing fasting glucose
levels according to the WHO criteria for diabetes mellitus
diagnosis and adjusting for all potential confounders, there
was still no association observed between increased levels of
fasting glucose and the risk of VT, with an OR of 097 (95%
CI 058–163) for the highest (≥7 mmol/l) versus the refer-
ence category (<61 mmol/l). Similar results were observed
for separate analyses for provoked and unprovoked VT. The
sensitivity analysis, which added self-reported diabetic indi-
viduals to the highest glucose level group, also yielded no
association by any of the different models. (Table SII).
Subsequently, fasting glucose concentrations were catego-
rized into quintiles. If anything, there was a weakly decreased
risk, with an 084-fold (95% CI 069–103), 077-fold (95%
CI 063–094), 074-fold (95% CI 061–092) and 073-fold
(95% CI 048–114) decreased risk of VT in the 2nd, 3rd, 4th
and 5th category of fasting glucose levels, respectively, com-
pared with the lowest reference category (Table SIII). The
sensitivity analysis in which the blood samples tested were
restricted to 2- to 4-h room temperature transportation
showed no association in different models. (Table SIV).
Self-reported diabetes was not associated with an increased
risk of VT (Table II), with an OR of 112 (95% CI 080–
158) in the fully adjusted model.
Discussion
Previous case-control studies provided evidence that hyper-
glycaemia was associated with the risk of VT, but in nearly
all these studies blood was drawn at the time of the throm-
botic event, where stress-induced hyperglycaemia either by
the thrombotic event (Hermanides et al, 2009; Tichelaar
et al, 2011) or surgery (Cohn et al, 2012) could have
occurred, leading to spurious results. In two large cohort
studies, no association was found between HbA1c and the
incidence of subsequent VT (Bell et al, 2013; Lerstad et al,
2014), where reverse causation could not have occurred.
While a limited number of cases were identified during fol-
low-up (n = 345 VT cases out of 12 298 participants and
n = 333 VT cases out of 16,156 participants, respectively),
these findings are consistent with our observations in the
current analysis.
Type 2 diabetes is considered a prothrombotic condition
in some studies, with the hypothesized mechanism of sup-
pressing fibrinolysis through increasing fibrinolytic inhibitor
PAI-1 (Plasminogen activator inhibitor-1) levels (Grant,
2007). Our null findings may for this reason come as surpris-
ing. Nevertheless, both a recent meta-analysis as well as an
individual patients meta-analysis of cohort studies are in line
with our findings, in which confounding was meticulously
taken into account (Gariani et al, 2016; Mahmoodi et al,
2017).
There are some strengths in the current study. Firstly, the
large sample size allowed for subgroup analysis. Secondly,
detailed information was available regarding many risk fac-
tors for VT to adjust for potential confounders. Thirdly, con-
ditional logistic regression in partner controls alone enabled
us to fully adjust for further confounding according to socio-
economic factors and lifestyle.
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Several limitations should also be considered. Firstly,
HbA1c levels, as a more accurate measure than fasting glu-
cose to reflect hyperglycaemia and diabetes status, were
not available in the study. Meanwhile, fasting glucose levels
were measured in patients after the first VT to surrogate
glucose levels before the event. However, it is possible that
the VT patients, in particular, adopted healthier lifestyles
after the disease, which led to decreased levels of fasting
glucose compared with the controls and therefore a weak-
ening of the association with VT. Secondly, we cannot rule
out misclassification by self-reported diabetes. However,
this misclassification was minimalized by including
medication use. Moreover, around 4% of current study
population self-reported as diabetes, which is comparable
to the Dutch diabetes prevalence of 4% in the period of
2001/2002 (data from Dutch Centraal Bureau voor de
Statistiek). Thirdly, the number of diabetic individuals was
limited in both the VT patients and controls, which
resulted in limited power in some of the subgroup
analyses.
In conclusion, our current findings confirm that neither
elevated fasting glucose levels in the non-diabetic population
nor self-reported diabetes are associated with an increased
risk of VT.
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Supporting Information
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Appendix S1.
Fig S1. Flowchart of sample selection from the MEGA
study. (A). The selection for the analysis of self-reported dia-
betes to the risk of a first event of VT, with the number of
cases and controls in the brackets. (B). The selection for the
analysis of hyperglycaemia in non-diabetic population to the
risk of VT.
Fig S2. Group average fasting glucose levels across seven
time interval categories, tested by one-way ANOVA and con-
trolled by age, sex, BMI and case/control status. The
numbers labelled above the dots in the figure corresponded
to the numbers of patients/controls falling into a time
interval category.
Table SI. Baseline characteristics
Table SII. Sensitivity analysis of the association of fasting
glucose levels categorized by the diabetes mellitus diagnosis
according to WHO criteria and the risk of a first event of
VT, by including self-reported diabetic individuals
Table SIII. The association of fasting glucose levels catego-
rized by the percentiles of the empirical fasting glucose distri-
bution in the control population and the risk of VT
Table SIV. Sensitivity analysis of taking the blood samples
with the time interval between two and four hours, and fast-
ing glucose were categorized by the percentiles of the empiri-
cal fasting glucose distribution in the controls
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